Lexicon Pharmaceuticals Inc (LXRX)
0.8634
+0.09
(+11.88%)
USD |
NASDAQ |
Nov 22, 16:00
0.8755
+0.01
(+1.40%)
After-Hours: 20:00
Lexicon Pharmaceuticals Research and Development Expense (Quarterly): 25.78M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 25.78M |
| June 30, 2024 | 17.64M |
| March 31, 2024 | 14.37M |
| December 31, 2023 | 14.76M |
| September 30, 2023 | 17.56M |
| June 30, 2023 | 14.54M |
| March 31, 2023 | 12.03M |
| December 31, 2022 | 13.98M |
| September 30, 2022 | 10.56M |
| June 30, 2022 | 13.36M |
| March 31, 2022 | 14.93M |
| December 31, 2021 | 16.50M |
| September 30, 2021 | 15.68M |
| June 30, 2021 | 10.26M |
| March 31, 2021 | 12.61M |
| December 31, 2020 | 0.992M |
| September 30, 2020 | 40.15M |
| June 30, 2020 | 57.30M |
| March 31, 2020 | 55.18M |
| December 31, 2019 | 40.61M |
| September 30, 2019 | 26.66M |
| June 30, 2019 | 12.64M |
| March 31, 2019 | 12.02M |
| December 31, 2018 | 12.31M |
| September 30, 2018 | 13.76M |
| Date | Value |
|---|---|
| June 30, 2018 | 26.48M |
| March 31, 2018 | 47.70M |
| December 31, 2017 | 42.57M |
| September 30, 2017 | 39.14M |
| June 30, 2017 | 26.93M |
| March 31, 2017 | 43.58M |
| December 31, 2016 | 26.22M |
| September 30, 2016 | 52.53M |
| June 30, 2016 | 48.22M |
| March 31, 2016 | 37.00M |
| December 31, 2015 | 30.44M |
| September 30, 2015 | 23.11M |
| June 30, 2015 | 20.77M |
| March 31, 2015 | 20.86M |
| December 31, 2014 | 20.03M |
| September 30, 2014 | 24.11M |
| June 30, 2014 | 21.19M |
| March 31, 2014 | 23.95M |
| December 31, 2013 | 20.26M |
| September 30, 2013 | 25.40M |
| June 30, 2013 | 23.69M |
| March 31, 2013 | 20.33M |
| December 31, 2012 | 20.99M |
| September 30, 2012 | 19.19M |
| June 30, 2012 | 19.36M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.992M
Minimum
Dec 2020
57.30M
Maximum
Jun 2020
20.94M
Average
14.84M
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris Inc | 198.40M |
| Halozyme Therapeutics Inc | 18.46M |
| Perspective Therapeutics Inc | 12.03M |
| Quanterix Corp | 8.104M |
| Autonomix Medical Inc | 1.174M |